Navigation Links
The Foundation for National Institutes of Health Announces Unprecedented Product Donation by sanofi-aventis in the U.S.
Date:8/5/2009

other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMEA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2008. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

    Contact:
    Noelle Boyd        Richard M. Scarfo
    Sanofi-aventis     Foundation for the National Institutes of Health
    (908) 981-6489     (301) 496-9921


'/>"/>
SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
2. More Than 230 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.3 Million for Arthritis Foundation
3. International Atomic Energy Agency and National Foundation for Cancer Research Launch Major Initiative to Improve Cancer Prevention and Treatments in Developing Countries
4. Melanoma Research Foundation and Seattle Cancer Care Alliance Host Educational Symposium and Reception for Melanoma Patients, Family Members and Healthcare Providers
5. Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal
6. The Parkinsons Disease Foundation Commemorates its 50th Anniversary with Special Scientific Symposium on Parkinsons Disease
7. Rutgers physicist earns prestigious Packard Foundation Science and Engineering Fellowship
8. Agendia BV Announces That its Chief Research Officer Laura van t Veer has Received a 2007 Breast Cancer Research Foundation Award
9. John Timberlake, Valeritas Executive Vice President and General Manager, Named Executive of the Year by the Diabetes Foundation
10. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
11. eHealth Initiative Foundation Launches Collaborative Research Effort to Improve Drug Safety

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...ewswire/-InimexPharmaceuticals,Inc.announcedtodayt...tandCEO. ,, Abramsbringsmorethan25yearsofdrugdi...ventorofthenuclearmedicineimagingagent,Cardiolite,...wasManager,BiomedicalResearchWorldwide.In1996,Abra...esidentandCEOfrom1996to2006.AnorMEDdiscoveredandde...
(Date:11/20/2009)...untries have an opportunity to take the lead in tw...e University of Valencia (UV), working together wi...tive fabric of the Spanish biotechnology industry....ectors have more clout than those in English-speak...d and plants has been overlooked by the leading co...
(Date:11/20/2009)...20 Cell Therapeutics, In...at the Ninth Circuit Court of Appeals reversed a U... be allowed to pursue all of its claims against Th...t Court for trial. CTI filed a complaint against ...ment consultant for CTI,s product TRISENOX, in 200...
(Date:11/19/2009)...PRNewswire-FirstCall/ -- Omeros Corporation (Nasda...ults for the third quarter ended September 30, 200...Omeros reported a net loss of $3.9 million, or $1....llion, or $2.54 per share, for the same period in ..., the Company reported a net loss of $15.5 million...
Breaking Biology Technology:Inimex Announces Appointment of New CEO 2Spanish biotechnology should focus on food and plant sectors to be more competitive 2Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8
...n throughout bioscience industry ... 14 A new report ranks Ohio best in,the Midwest f...on and,business growth, according to the Ohio Busi...rganization that markets the state for capital,inv...Cleveland, Ohio-based,bioscience incubator, shows ...
... Institute,(KGI) today announced the election of t...ne M. Burzik, chief executive officer of Kinetic C...resident for manufacturing at,Gilead Sciences; and...Burling LLP. KGI,s board consists of leaders in b...e formation of KGI since its founding in 1997. Wit...
...gust 16 /PRNewswire-FirstCall/,-- Santhera Pharmac...y,pharmaceutical company with a focus on neuromusc...imited (TSE:4502, "Takeda"), jointly announced,tod...ccepted the filing of,the Marketing Authorization ...-MC17 (INN: idebenone, originally developed by Tak...
Other Biology Technology:Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry 2KGI Elects Three New Members to Board of Trustees 2European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera 2European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera 3European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera 4European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera 5European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera 6
(Date:11/23/2009)...ng of recent discoveries about the multiple health...s multi-purpose nutrient, increased awareness of t... spurred research and even led to an appreciation ...ing from the health of your immune system to preve...nfluenza, vitamin D is now seen as one of the most...
(Date:11/23/2009)...of General Medical Sciences (NIGMS), part of the N...42.3 million for grants in scientific areas it ide...ed the GO grant program to stimulate biomedical re... American Recovery and Reinvestment Act (Recovery ...e to have a significant impact on a field of biome...
(Date:11/23/2009)...aled how environmental irritants such as air pollu... research published today in the American Journal...uthors of the study, from Imperial College London ...action inside the lungs that can trigger coughing ...n the air. They suggest that their findings may ul...
Breaking Biology News(10 mins):Multiple health concerns surface as winter, vitamin D deficiences arrive 2Multiple health concerns surface as winter, vitamin D deficiences arrive 3NIGMS invests in scientific Grand Opportunities with Recovery Act funds 2NIGMS invests in scientific Grand Opportunities with Recovery Act funds 3Research reveals exactly how coughing is triggered by environmental irritants 2Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 1Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 2Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 3Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 4Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 5Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 6Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 7Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 8Antigen Discovery Inc Awarded Grant for Chlamydia Vaccine Development 14163 1Antigen Discovery Inc Awarded Grant for Chlamydia Vaccine Development 14163 2Life Science Firms are Turning to Firmex to do Deals Online 14161 1Life Science Firms are Turning to Firmex to do Deals Online 14161 2Life Science Firms are Turning to Firmex to do Deals Online 14161 3
... have discovered a new, more accurate, method of m...kthrough that could lead to more effective treatme.... , Dr. Pietro Mastroeni, Professor Duncan Maskel...teams have pioneered the integration of mathematic...pread of individual bacteria within the human body...
... them had narrow, pointed teeth, which were more s...em. But how did they then grind their food? Until ...ere helped by stones which they swallowed. In thei...gastric mill,. But this assumption does not seem t... Bonn and Tübingen have now proved. Their research...
...te neuronal signaling in the brain and spinal cord...e with a mutation affecting a neuronal zinc target... zinc in modulating signaling among the neurons. S...e same exaggerated response to noise as children w... or hyperekplexia. , The findings shed light on a ...
Other Biology News:Researchers map spread of pathogens in the human body 2Dinosaurs -- stones did not help with digestion 2Dinosaurs -- stones did not help with digestion 3Zinc plays important role in brain circuitry 2
Normal Porcine Serum from Equitech-Bio
Anti-Foam Reagent from Promega
Viral CCI, Unconjugated, Fc Chimera from R&D Systems
GENOMIPHI V2 DNA AMP KIT 25RXN from GE Healthcare, formerly Amersham Biosciences
Biology Products: